Categories: News

Sight Sciences to Present at the Upcoming Piper Sandler Virtual Ophthalmology & Diabetes Symposium

MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to participate in the upcoming Piper Sandler Virtual Ophthalmology & Diabetes Symposium.

Sight Sciences’ management is scheduled to participate in a fireside chat Monday, May 23, 2022, at 10:00am PT. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the company’s website at: https://investors.sightsciences.com/.

About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease.

For more information, visit www.sightsciences.com.

OMNI® and TearCare® are registered trademarks of Sight Sciences.
© 2022 Sight Sciences. All rights reserved.

Media contact:
Shay Smith
Health+Commerce
707.971.9779
shay@healthandcommerce.com

Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com

Staff

Recent Posts

BioSonic Bloom: What Published Research Says About 528 Hz and 432 Hz Audio Frequency Programs

An In-Depth Analysis of Digital Sound Frequency Programs, Binaural Beats Research, and Key Considerations for…

4 hours ago

Best TRT Injection for 2026: Fridays Lists Prescription Testosterone in Injectable and Oral Formats as Men Compare Telehealth Hormone Options

Independent analysis examines Fridays' published TRT program structure, delivery format options, and what clinical research…

4 hours ago

How Does Ozempic Work For Weight Loss? Best Weight Loss Supplement Launch By PhenQ

Ozempic for Weight Loss: Does It Work and Is It Safe? Read PhenQ Details –…

4 hours ago

Best NAD+ Injection for 2026: Sprout Health Lists Compounded NAD+ at $149 First Month as Telehealth Longevity Programs Expand

Prescription NAD+ Injection Access, At-Home Administration Models, Compounding Standards, and What Consumers Should Know Before…

4 hours ago

Is SynergyRx GLP-1 Legitimate? Platform Lists Compounded Semaglutide at $200 With Oral Tablet Options

Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…

1 day ago